Kansas Officials Announce
Agreement for Bioprocessing Facility in Junction City
Facility for plant-made pharmaceuticals continues Kansas’ advancement
in biotechnology
Junction City, Kan. – September 29, 2006 - Kansas state
officials announced Friday the signing of an agreement that will
bring a bioprocessing facility for plant-made pharmaceuticals to
Junction City. State officials said the opening of the plant by
Ventria Bioscience of Sacramento, Calif., is a significant advancement
in Kansas’ involvement in bioscience.
“Agriculture has long been the backbone of the Kansas economy,
so it’s appropriate we would embrace this opportunity to
make the most of scientific advances in plant-made pharmaceuticals,” said
Kansas Governor Kathleen Sebelius in a statement. “I welcome
Ventria Bioscience to Kansas and look forward to their contributions
to the health of children worldwide.”
Ventria is developing products that enhance human health. A recent
clinical study showed that Ventria’s product helped reduce
the duration of diarrhea in children by 30 percent, from 5.2 days
to 3.7 days, as part of an oral rehydration solution. Childhood
diarrhea is the second leading killer of children, claiming 1.9
million lives annually according to the World Health Organization.
The facility, to be located in Junction City, will process a variety
of rice developed by Ventria. Proteins extracted from the rice
will be incorporated into oral rehydration solutions to address
childhood diarrhea. Ventria is also developing other products using
these proteins. The rice itself is then discarded.
Junction City led the effort to attract Ventria to Kansas.
“The bioprocessing facility is an exciting opportunity for
new jobs in Junction City and is expected to contribute $40 million
to the Kansas economy by the time it is fully operational,” said
Junction City Mayor Terry Heldstab.
Farmers are expected to be among the project’s major beneficiaries,
as those who grow the rice that supplies the facility can earn
a premium compared to their next most lucrative crop, said Kansas
Agriculture Secretary Adrian Polansky.
“This is as an important development for Kansas farmers,
who stand to benefit from the additional income,” he said. “They
also have the satisfaction of knowing they are helping provide
affordable healthcare products to children who desperately need
it.”
Ventria CEO Scott Deeter said the decision to establish this part
of his company’s operations
in Kansas was the result of an impressive, coordinated effort by
key players at the state level, as well as on the local level in
Junction City.
“The new bioprocessing facility in Junction City will provide
the infrastructure to deliver affordable healthcare solutions on
a global basis to those who need it most,” said Deeter. “In
working with Kansas to choose this location, we have been extremely
impressed by the state’s clear commitment to biotechnology,
its support of the growing field of plant-made pharmaceuticals,
and its understanding of how this field will improve healthcare
for all.”
The effort to attract Ventria to Kansas involved a number of players,
including Governor Kathleen Sebelius, Secretary of Agriculture
Adrian Polansky, the Kansas Department of Commerce, Junction City
and Geary County, Kansas Technology Enterprise Corporation (KTEC),
KansasBIO, Kansas State University and Kansas Farm Bureau.
“This announcement today is very satisfying, as KTEC and
our partners have worked for over a year to bring Ventria’s
operation to Kansas,” said Tracy Taylor, President and CEO
of KTEC. “Strategically, Ventria provides an outstanding
opportunity for Kansas, given our agricultural strengths and focus
on the biosciences.”
For more information on plant-made pharmaceuticals visit:
http://www.plantpharma.org
http://www.bio.org/healthcare/pmp.
For more information on the announcement contact:
Ventria Bioscience
http://www.Ventria.com
Sarah Fuhrmann
1-877-835-8362 ext. 2006
Statements in this announcement other than historical data and
information constitute forward looking statements that involve
risks and uncertainties that could cause actual results to differ
materially from those stated or implied by such forward-looking
statements. Potential risks and uncertainties may include, but
are not limited to, recent changes in senior management, fluctuations
in operating results, market conditions and changes in technology
and increased competition.
|